HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

BGM

BGM Group Ltd. (NASDAQ)

Healthcare — Drug Manufacturers - Specialty & Generic

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform. BGM Group Ltd. is based in Chengdu, China.

None
$0.36
$0.00 (-1.09%)
Sign in to add BGM to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$145.63M
P/E Ratio (TTM)-
Forward P/E-
EPS (TTM)$-0.29
Dividend Yield-
Profit Margin-
Revenue Growth13.90%
ROE-
Debt/Equity0.97
Recommendation None
Analyst Target-
Analysts-
Indexes NASDAQ

Technical Indicators

RSI (14)42.9
Beta-
SMA 20-
SMA 40-
52-Week High$11.80
52-Week Low$0.26
50-Day Avg$0.33
200-Day Avg$3.82
Avg Volume357.0K
Volume24.2K

Performance Analysis

NEUTRAL

BGM presents a mixed picture with both positive and negative indicators.

+ Trading near its 52-week low ($0.26), which could present a value opportunity.
~ RSI at 42.9 is in neutral territory.
~ Modest revenue growth of 13.9% year-over-year.
~ Wall Street consensus is "none".

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 12:59 UTC

Back to Screener Export Report